HBO is returning to Batman’s rogues gallery. A Poison Ivy series is in development at the network, with Lauren LeFranc attached as a producer, Variety confirmed. LeFranc was the executive producer and showrunner behind The Penguin, the HBO series that turned a supporting villain from Matt Reeves’ The Batman into one of 2024’s most awarded limited series.
Poison Ivy has never led a film or TV series. She has been a supporting presence across DC titles: Uma Thurman played her in 1997’s Batman & Robin, and the character has appeared in live-action shows such as Gotham and Batwoman, along with animated projects including Harley Quinn. That gap is exactly what makes the development worth watching.
The Penguin playbook
The strongest signal here is not the character; it is the talent. The Penguin was the first live-action spinoff from a Batman movie. It aired on HBO in 2024 and delivered awards-season results: Colin Farrell won an Emmy and a Golden Globe for his lead performance, and the series picked up several best limited series nominations. For Warner Bros. Discovery, that validated a specific model: take a known villain, give the story a genre lane, and treat it as premium television rather than IP filler.
LeFranc’s involvement suggests Poison Ivy will be sold with the same ambition. Media planners should read it as another piece of appointment-viewing inventory aimed at prestige drama buyers, not just comic-book fans.
A crowded DC slate
The project arrives as DC’s screen universe splits into multiple lanes. The latest expansion, Clayface, is unconnected to Robert Pattinson and Reeves’ Batman world. HBO also has The People vs. Gorilla Grodd, a comedic, villain-focused spinoff from James Gunn’s Superman movie, scheduled for 2027. Reeves’ own The Batman Part 2 is set for 2028.
What the report does not specify is which continuity Poison Ivy belongs to. That matters more than usual:
- Reeves universe: grounded, crime-first tone and a path to the 2028 Batman sequel.
- Gunn DCU: broader comic-book tone and cross-title marketing upside.
- Standalone: creative freedom but less franchise support.
For entertainment marketers, the universe question affects casting noise, creative expectations and how early you can attach brand partners. For streaming analysts, it determines whether this becomes a flagship title or another crowded slate item.
What to watch next
Development is not a greenlight. There is no writer, cast or premiere timing in the report yet. But after The Penguin, a Batman villain series is no longer a novelty; it is a proven format. If HBO moves quickly, Poison Ivy becomes the clearest test of whether that format can travel beyond a single breakout hit.
Source: Variety
